141.72

0.19% 0.0173

Neurocrine Biosciences Inc (NBIX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Dividendenhistorie

Schlusskurs vom Vortag:

$141.70

Offen:

$141.78

24-Stunden-Volumen:

75,178

Relative Volume:

0.08

Marktkapitalisierung:

$14.14B

Einnahmen:

$2.41B

Nettoeinkommen (Verlust:

$305.80M

KGV:

48.04

EPS:

2.95

Netto-Cashflow:

$492.20M

1W Leistung:

-8.26%

1M Leistung:

+2.41%

6M Leistung:

+11.52%

1J Leistung:

+4.82%

1-Tages-Spanne:

$141.52

$142.51

1-Wochen-Bereich:

$141.52

$155.55

52-Wochen-Spanne:

$84.23

$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Firmenname

Neurocrine Biosciences Inc

Sektor

Healthcare (1136)

Branche

Drug Manufacturers - Specialty & Generic (85)

Telefon

(858) 617-7600

Adresse

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Mitarbeiter

1,800

Twitter

Nächster Verdiensttermin

2024-10-30

Neueste SEC-Einreichungen

NBIX's Discussions on Twitter

Vergleichen Sie NBIX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NBIX Neurocrine Biosciences Inc	141.79	14.13B	2.41B	305.80M	492.20M	2.95
ZTS Zoetis Inc	125.09	53.87B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	14.75	45.71B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	9.885	43.73B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	30.27	34.49B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	506.76	22.00B	3.08B	1.24B	1.07B	25.61

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-21	Eingeleitet	Citigroup	Buy
2025-07-21	Eingeleitet	Truist	Buy
2025-07-10	Eingeleitet	Goldman	Buy
2025-04-15	Hochstufung	Needham	Hold → Buy
2025-04-14	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2025-02-11	Eingeleitet	Deutsche Bank	Hold
2024-10-10	Fortgesetzt	Raymond James	Outperform
2024-08-29	Hochstufung	Piper Sandler	Neutral → Overweight
2024-04-24	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-12-13	Fortgesetzt	Citigroup	Neutral
2023-12-12	Eingeleitet	Deutsche Bank	Buy
2023-10-24	Fortgesetzt	Cantor Fitzgerald	Overweight
2023-08-21	Bestätigt	Mizuho	Neutral
2023-07-24	Hochstufung	SVB Securities	Market Perform → Outperform
2023-07-06	Hochstufung	BMO Capital Markets	Underperform → Market Perform
2023-05-04	Hochstufung	Guggenheim	Neutral → Buy
2023-03-30	Hochstufung	Canaccord Genuity	Hold → Buy
2023-03-03	Hochstufung	Evercore ISI	In-line → Outperform
2023-02-03	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-11-14	Herabstufung	Evercore ISI	Outperform → In-line
2022-10-11	Eingeleitet	UBS	Buy
2022-09-26	Eingeleitet	Wells Fargo	Equal Weight
2022-06-06	Fortgesetzt	Jefferies	Buy
2022-03-03	Herabstufung	Piper Sandler	Overweight → Neutral
2022-02-25	Hochstufung	Goldman	Neutral → Buy
2022-01-18	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2021-11-19	Eingeleitet	BMO Capital Markets	Underperform
2021-11-17	Hochstufung	JP Morgan	Neutral → Overweight
2021-10-14	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-09-23	Fortgesetzt	Needham	Hold
2021-08-06	Herabstufung	Canaccord Genuity	Buy → Hold
2021-05-18	Fortgesetzt	Goldman	Neutral
2021-05-06	Hochstufung	Barclays	Equal Weight → Overweight
2021-02-02	Eingeleitet	Raymond James	Outperform
2020-09-30	Eingeleitet	The Benchmark Company	Hold
2020-08-04	Herabstufung	JP Morgan	Overweight → Neutral
2020-06-29	Herabstufung	Goldman	Buy → Neutral
2020-06-09	Eingeleitet	Wedbush	Outperform
2020-03-06	Eingeleitet	Citigroup	Buy
2020-02-27	Eingeleitet	Barclays	Equal Weight
2020-02-24	Eingeleitet	William Blair	Outperform
2020-02-06	Eingeleitet	Mizuho	Neutral
2020-02-05	Bestätigt	H.C. Wainwright	Buy
2019-12-13	Herabstufung	Credit Suisse	Outperform → Neutral
2019-08-07	Eingeleitet	RBC Capital Mkts	Outperform
2019-07-16	Eingeleitet	Oppenheimer	Outperform
2019-06-05	Eingeleitet	Guggenheim	Neutral
2019-05-21	Eingeleitet	Credit Suisse	Outperform
2019-04-22	Hochstufung	JP Morgan	Neutral → Overweight
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2019-02-06	Bestätigt	BofA/Merrill	Buy
2019-01-23	Herabstufung	JP Morgan	Overweight → Neutral
2018-12-13	Eingeleitet	Goldman	Buy
2018-11-21	Eingeleitet	Canaccord Genuity	Buy

Alle ansehen

Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten

07:46 AM

Neurocrine Bio. stock price target raised to $198 by H.C. Wainwright - Investing.com UK

07:46 AM

07:31 AM

Published on: 2025-12-18 16:31:37 - Улправда

07:31 AM

Dec 17, 2025

HC Wainwright & Co. Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq

Dec 17, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 1,190 Shares - MarketBeat

Dec 17, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Director Leslie Norwalk Sells 5,000 Shares - MarketBeat

Dec 17, 2025

Neurocrine Biosciences Director Sells Shares - TradingView — Track All Markets

Dec 17, 2025

Neurocrine Bio. stock price target reiterated at $200 by TD Cowen - Investing.com Canada

Dec 17, 2025

Key facts: HC Wainwright maintains 'Buy' on Neurocrine; price target rises - TradingView — Track All Markets

Dec 17, 2025

Neurocrine Bio. stock holds Buy rating at Jefferies after R&D Day - Investing.com Canada

Dec 17, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Dec 17, 2025

Neurocrine Bio. stock rating reiterated at Outperform by RBC Capital - Investing.com Canada

Dec 17, 2025

Texas Permanent School Fund Corp Sells 11,976 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 17, 2025

Neurocrine showcases R&D across neuroscience and endocrinology - The Pharma Letter

Dec 17, 2025

Dec 16, 2025

Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology - PR Newswire

Dec 16, 2025

Dec 15, 2025

What analysts say about Neurocrine Biosciences Inc stockMomentum Trading Signals & Free Daily Top Stock Picks for All Investors - earlytimes.in

Dec 15, 2025

Dir Norwalk Files To Sell 11,250 Of Neurocrine Biosciences Inc [NBIX] - TradingView — Track All Markets

Dec 15, 2025

Hudson Bay Capital Management LP Has $9.75 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 15, 2025

Dec 14, 2025

Neurocrine Biosciences (NBIX): Revisiting Valuation After a Year of Double-Digit Shareholder Returns - simplywall.st

Dec 14, 2025

Thrivent Financial for Lutherans Cuts Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 14, 2025

Dec 13, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat

Dec 13, 2025

Boone Capital Management LLC Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Dec 13, 2025